サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1584079

サイトメガロウイルス（CMV）検査市場：サンプルタイプ別、薬剤タイプ別、検査タイプ別、エンドユーザー別、用途別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測

Cytomegalovirus (CMV) Tests Market, By Sample Type, By Drug Type, By Test Type, By End User, By Application, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 316 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
サイトメガロウイルス（CMV）検査市場：サンプルタイプ別、薬剤タイプ別、検査タイプ別、エンドユーザー別、用途別、国別、地域別 - 産業分析、市場規模、市場シェア、2024年～2032年の予測
出版日: 2024年10月26日
発行: AnalystView Market Insights
ページ情報: 英文 316 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

サイトメガロウイルス（CMV）検査の市場規模は、2023年に4,990万米ドルとなり、2024年から2032年にかけてCAGR1.01％で拡大

サイトメガロウイルス（CMV）検査市場 - 市場力学

サイトメガロウイルス（CMV）感染症の新興国市場における治療普及率の上昇、ウイルスに対する意識の高まり、より効果的な新しい治療法の開発が市場需要を促進

ほとんどの医師は、胎児異常や反復流産の疑いがある患者に対してサイトメガロウイルス（CMV）検査を推奨しており、市場成長に寄与しています。CMV検査は、免疫不全の人や乳幼児に深刻な病気を引き起こす可能性のあるこのウイルスを検出するために不可欠です。広く分布する病原体として、CMVは世界的に先天性感染症の主要な原因となっています。CMVはヒトヘルペスウイルスの一種で、感染した体液との親密な接触や、経胎盤移植、輸血、臓器移植などを介して感染します。CMV治療市場は、CMV感染症の有病率の上昇、ウイルスに対する意識の高まり、より効果的な新しい治療法の開発など、いくつかの要因によって支えられています。一般的なCMV治療には、抗ウイルス薬、免疫グロブリン療法、幹細胞移植などがあります。この市場はさらに、慢性疾患の罹患率の増加、個別化医療の需要、新興諸国における治療の利用可能性の増加によって牽引されています。2023年8月にNational Library of Medicineが発表した論文によると、6歳以上の約59％がCMVに感染しており、血清有病率は年齢が高くなるにつれて増加しています。CMV感染は、一次感染、再感染、再活性化として現れ、血液製剤、授乳、密接な接触環境、周産期感染、性的接触など様々なトランスミッションを通じて起こります。再活性化は、罹患率および死亡率の上昇を伴うため、免疫不全患者において特に問題となります。免疫に異常のない人がCMVに感染して死亡することはまれですが、化学療法を受けていたり、コルチコステロイドを服用していたりする免疫不全患者では、重大な健康問題を引き起こす可能性があります。骨髄移植後、CMVに関連した死亡率は10％から75％と報告されており、CMV治療市場をさらに押し上げています。さらに、CMVは先進国では成人の約60％から70％、新興国ではほぼ100％が感染しています。ヘルペスウイルスの中で、CMVは自然免疫反応と適応免疫反応の両方を回避するように特別に設計された遺伝子の数が最も多いです。このウイルスはT細胞の抗原監視に負担をかけ、免疫機能不全の一因となっています。さらに、先天性CMVは学習障害、難聴、知的障害の主な感染要因であり、CMV治療市場の重要な促進要因となっています。

サイトメガロウイルス（CMV）検査市場 - 主要洞察

当社のリサーチアナリストが共有した分析によると、世界市場は予測期間（2024年～2032年）に約1.01%のCAGRで毎年成長すると予測されています。

検査タイプ別では、核酸増幅検査（NAAT）が2023年に最大市場シェアを示すと予測されます。

薬剤タイプ別では、2023年にはバルガンシクロビルが主要タイプになりました。

地域別では、北米が2023年の主要収益源となりました。

サイトメガロウイルス（CMV）検査市場 - セグメンテーション分析：

サイトメガロウイルス（CMV）検査の世界市場は、サンプルタイプ、薬剤タイプ、検査タイプ、エンドユーザー、用途、地域に基づいてセグメント化されます。

検査タイプ別では、酵素免疫測定/酵素結合免疫吸着測定法（EIA/ELISA）、核酸増幅検査（NAAT）、その他のCMV検査に分類されます。このうち、CMV核酸増幅検査（NAAT）セグメントは、主にウイルスDNAを検出する感度と特異性が高いことから、2023年の市場シェアをリードしました。NAATは、特に免疫不全患者におけるCMV感染の早期かつ正確な診断を可能にするため、臨床現場において特に有利です。

市場は薬剤タイプによって5つのカテゴリーに分類されます：バルガンシクロビル、ガンシクロビル、シドホビル、フォスカルネット、その他です。サイトメガロウイルス（CMV）検査市場では、バルガンシクロビルが主要な薬剤タイプとして際立っています。その主な理由は、経口バイオアベイラビリティと、特に免疫不全患者におけるCMV感染症の予防と治療における有効性です。ガンシクロビルのような静脈内投与と比較して投与が容易であるため、臨床現場での人気が高まっています。特に急性期においてはガンシクロビルが依然として重要であり、耐性症例にはシドホビルやフォスカルネットなどの他の薬剤が使用されていますが、バルガンシクロビルの実証された有効性と使いやすい投与方法によって、ヘルスケア専門家の間ではバルガンシクロビルが好ましい選択肢となっています。この動向は、CMV感染を管理する上で、より患者中心の治療ソリューションに向けた幅広い動きを強調するものです。

サイトメガロウイルス（CMV）検査市場 - 地理的洞察

北米はサイトメガロウイルス（CMV）検査市場の主要地域です。その主な理由は、高度なヘルスケアインフラ、抗生物質耐性感染症の高い流行率、研究開発への多額の投資です。同地域の病院は、MRSAのような深刻なグラム陽性感染症を管理するために、抗生物質、特にバンコマイシンを大量に消費しています。さらに、サイトメガロウイルス（CMV）検査の需要拡大には、規制の枠組みや感染管理の重視が貢献しています。この地域には主要な製薬企業が存在し、臨床試験が進行中であるため、市場でのリーダーシップがさらに強化されています。

サイトメガロウイルス（CMV）検査市場 - 競合情勢：

CMV検査市場の企業は、市場での存在感を高め、イノベーションを促進するために様々な戦略を採用しています。主な焦点は、検査法の感度と特異度を高め、迅速な診断ソリューションを生み出すための研究開発への投資です。ヘルスケアプロバイダーや検査施設とのコラボレーションは、検査プロセスを合理化し、臨床ニーズへの洞察を集めるのに役立ちます。マーケティング活動では、ヘルスケア専門家や医療機関を対象に、CMV関連疾患の早期発見と管理の重要性を強調しています。さらに、各社はCMVのリスクに関する認識を高めるための教育キャンペーンに取り組み、検査製品やサービスの市場を拡大しています。

目次

第1章 サイトメガロウイルス（CMV）検査市場概要

  • 調査範囲
  • 市場推定年

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 サイトメガロウイルス（CMV）検査の主要市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 サイトメガロウイルス（CMV）検査業界調査

  • PEST分析
  • ポーターのファイブフォース分析
  • 成長見通しマッピング
  • 規制枠組み分析

第5章 サイトメガロウイルス（CMV）検査市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 サイトメガロウイルス（CMV）検査市場情勢

  • サイトメガロウイルス（CMV）検査市場シェア分析、2023年
  • 内訳データ：主要メーカー別
    • 既存企業の分析
    • 新興企業の分析

第7章 サイトメガロウイルス（CMV）検査市場 - サンプルタイプ別

  • 概要
    • セグメントシェア分析：サンプルタイプ別
    • 尿
    • 血

第8章 サイトメガロウイルス（CMV）検査市場 - 薬剤タイプ別

  • 概要
    • セグメントシェア分析：薬剤タイプ別
    • バルガンシクロビル
    • ガンシクロビル
    • シドフォビル
    • フォスカーネット
    • その他

第9章 サイトメガロウイルス（CMV）検査市場 - 検査タイプ別

  • 概要
    • セグメントシェア分析：検査タイプ別
    • 酵素免疫測定法/酵素結合免疫吸着測定法（EIA/ELISA）検査
    • 核酸増幅検査（NAAT）
    • その他のCMV検査

第10章 サイトメガロウイルス（CMV）検査市場 - エンドユーザー別

  • 概要
    • セグメントシェア分析：エンドユーザー別
    • 病院
    • 診断センター
    • クリニック
    • その他

第11章 サイトメガロウイルス（CMV）検査市場 - 用途別

  • 概要
    • セグメントシェア分析：用途別
    • 網膜炎
    • 肺炎
    • 胃腸潰瘍
    • 脳炎
    • 幹細胞移植
    • 臓器移植
    • その他（口内炎、咽頭炎など）

第12章 サイトメガロウイルス（CMV）検査市場 - 地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • イタリア
    • 英国
    • フランス
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋（APAC）
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 日本
    • 韓国
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第13章 主要ベンダー分析 - サイトメガロウイルス（CMV）検査業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Pfizer Inc.
    • GlaxoSmithKline plc
    • Novartis AG
    • Mylan N.V.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • F. Hoffmann-La Roche Ltd.
    • Zydus Cadila
    • Lupin
    • Cipla Inc.
    • Aurobindo Pharma
    • Glenmark Pharmaceuticals Limited
    • Endo International plc
    • AstraZeneca
    • Johnson & Johnson Private Limited
    • Bio-Rad Laboratories, Inc.
    • BD
    • その他

第14章 アナリストの全方位展望

目次
Product Code: ANV4075

REPORT HIGHLIGHT

Cytomegalovirus (CMV) Tests Market size was valued at USD 49.90 Million in 2023, expanding at a CAGR of 1.01% from 2024 to 2032.

Cytomegalovirus (CMV) tests are diagnostic tools designed to identify the presence of CMV, a widespread virus that can lead to serious health complications, particularly in immunocompromised individuals and newborns. These tests often utilize laboratory techniques, including polymerase chain reaction (PCR) for detecting viral DNA, as well as serological methods to identify the antibodies against CMV. Early detection is vital for managing potential complications, such as congenital CMV infection in infants or opportunistic infections in transplant recipients. Accurate testing enables timely intervention and monitoring, making CMV testing a critical aspect of healthcare for at-risk populations.

Cytomegalovirus (CMV) Tests Market- Market Dynamics

Increasing incidence prevalence of the CMV infections, increased awareness about virus, and the development of new and more effective treatment options to propel market demand

Most physicians recommend cytomegalovirus (CMV) tests for patients with suspected fetal abnormalities or recurrent miscarriages, contributing to market growth. CMV tests are essential for detecting this virus, which can lead to serious illnesses in immunocompromised individuals and infants. As a widely distributed pathogen, CMV is the leading cause of congenital infections globally. It is a human herpesvirus that can be transmitted through intimate contact with infected bodily fluids, as well as via transplacental transfer, blood transfusions, or organ transplants. The CMV treatment market is propelled by several factors, including the rising prevalence of CMV infections, increased awareness about the virus, and the development of new and more effective treatment options. Common CMV treatments include antiviral medications, immunoglobulin therapy, and stem cell transplantation. This market is further driven by the growing incidence of chronic diseases, the demand for personalized medicine, and the increasing availability of treatments in developing countries. According to an August 2023 article published by the National Library of Medicine, approximately 59% of individuals over six years old have encountered CMV, with seroprevalence increasing with age. CMV infections can manifest as primary infections, reinfections, or reactivations, occurring through various transmission modes such as blood products, breastfeeding, close-contact settings, perinatal transmission, and sexual contact. Reactivation is particularly concerning in immunocompromised patients, as it is associated with increased morbidity and mortality. For individuals with intact immunity, CMV rarely results in death; however, in immunocompromised patients undergoing chemotherapy or taking corticosteroids, it can lead to significant health issues. Following bone marrow transplants, reported mortality rates related to CMV vary between 10% and 75%, further boosting the CMV treatment market. Moreover, CMV infects approximately 60% to 70% of adults in industrialized countries and nearly 100% in emerging countries. Among herpesviruses, CMV has the largest number of genes specifically designed to evade both innate and adaptive immune responses. This virus poses a burden on T-cell antigenic surveillance and contributes to immune dysfunction. Additionally, congenital CMV is a primary infectious cause of learning disabilities, deafness, and intellectual disabilities, making it a significant driver for the CMV treatment market.

Cytomegalovirus (CMV) Tests Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 1.01% over the forecast period (2024-2032)

Based on Test Type segmentation, nucleic acid amplification tests (NAATs) was predicted to show maximum market share in the year 2023

Based on Drug Type segmentation, Valganciclovir was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Cytomegalovirus (CMV) Tests Market- Segmentation Analysis:

The Global Cytomegalovirus (CMV) Tests Market is segmented on the basis of Sample Type, Drug Type, Test Type, End User, Application, and Region.

The market is divided into three categories based on Test Type: enzyme immunoassay/enzyme-linked immunosorbent assay (EIA/ELISA) tests, nucleic acid amplification tests (NAATs), and other CMV tests. Among these, the CMV nucleic acid amplification tests (NAATs) segment led the market share in 2023, primarily due to their high sensitivity and specificity in detecting viral DNA. NAATs are particularly advantageous in clinical settings because they enable early and accurate diagnosis of CMV infections, especially in immunocompromised patients, where timely intervention is critical to preventing severe complications.

The market is divided into five categories based on Drug Type: Valganciclovir, Ganciclovir, Cidofovir, Foscarnet and Others. In the cytomegalovirus (CMV) tests market, Valganciclovir stands out as the leading drug type, largely due to its oral bioavailability and effectiveness in preventing and treating CMV infections, especially in immunocompromised patients. Its ease of administration compared to intravenous alternatives like Ganciclovir enhances its popularity in clinical settings. Although Ganciclovir remains significant, particularly in acute situations, and other medications such as Cidofovir and Foscarnet are employed for resistant cases, Valganciclovir's proven efficacy and user-friendly administration make it the preferred option among healthcare professionals. This trend underscores a wider movement toward more patient-centric treatment solutions in managing CMV infections.

Cytomegalovirus (CMV) Tests Market- Geographical Insights

North America is the dominating region in the Cytomegalovirus (CMV) Tests market, primarily due to its advanced healthcare infrastructure, high prevalence of antibiotic-resistant infections, and significant investments in research and development. The region's hospitals are major consumers of these antibiotics, particularly Vancomycin, to manage serious Gram-positive infections like MRSA. Furthermore, supportive regulatory frameworks and a strong emphasis on infection control contribute to the growing demand for Cytomegalovirus (CMV) Tests. The presence of key pharmaceutical companies and ongoing clinical trials in this region further enhance its market leadership.

Cytomegalovirus (CMV) Tests Market- Competitive Landscape:

Companies in the CMV tests market adopt various strategies to strengthen their market presence and foster innovation. A primary focus is on investing in research and development to enhance the sensitivity and specificity of testing methods while creating rapid diagnostic solutions. Collaborations with healthcare providers and laboratories help streamline testing processes and gather insights into clinical needs. Marketing initiatives highlight the significance of early detection and management of CMV-related conditions, targeting healthcare professionals and institutions. Additionally, companies engage in educational campaigns to raise awareness about CMV risks, thereby expanding the market for their testing products and services.

Recent Developments:

In September 2022, ProBioGen entered into an agreement with the City of Hope to manufacture the CMV vaccine for clinical trials and commercial distribution, accelerating the development and production of the vaccine that could potentially save numerous lives.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Mylan N.V.
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi
  • F. Hoffmann-La Roche Ltd.
  • Zydus Cadila
  • Lupin
  • Cipla Inc.
  • Aurobindo Pharma
  • Glenmark Pharmaceuticals Limited
  • Endo International plc
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Bio-Rad Laboratories, Inc.
  • BD
  • Others

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY SAMPLE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Urine
  • Blood

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY DRUG TYPE- MARKET ANALYSIS, 2019 - 2032

  • Valganciclovir
  • Ganciclovir
  • Cidofovir
  • Foscarnet
  • Others

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY TEST TYPE- MARKET ANALYSIS, 2019 - 2032

  • Enzyme immunoassay/enzyme-linked immunosorbent assay (EIA/ELISA) tests
  • Nucleic acid amplification tests (NAATs)
  • Other CMV tests

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Diagnostic Centres
  • Clinics
  • Others

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Retinitis
  • Pneumonia
  • Gastrointestinal ulcers
  • Encephalitis
  • Stem cell transplantation
  • Organ transplantation
  • Others (Mouth Ulcers, Pharyngitis, etc.)

GLOBAL CYTOMEGALOVIRUS (CMV) TESTS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Cytomegalovirus (CMV) Tests Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Cytomegalovirus (CMV) Tests Market Snippet by Sample Type
    • 2.1.2. Cytomegalovirus (CMV) Tests Market Snippet by Drug Type
    • 2.1.3. Cytomegalovirus (CMV) Tests Market Snippet by Test Type
    • 2.1.4. Cytomegalovirus (CMV) Tests Market Snippet by End User
    • 2.1.5. Cytomegalovirus (CMV) Tests Market Snippet by Application
    • 2.1.6. Cytomegalovirus (CMV) Tests Market Snippet by Country
    • 2.1.7. Cytomegalovirus (CMV) Tests Market Snippet by Region
  • 2.2. Competitive Insights

3. Cytomegalovirus (CMV) Tests Key Market Trends

  • 3.1. Cytomegalovirus (CMV) Tests Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Cytomegalovirus (CMV) Tests Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Cytomegalovirus (CMV) Tests Market Opportunities
  • 3.4. Cytomegalovirus (CMV) Tests Market Future Trends

4. Cytomegalovirus (CMV) Tests Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Cytomegalovirus (CMV) Tests Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Cytomegalovirus (CMV) Tests Market Landscape

  • 6.1. Cytomegalovirus (CMV) Tests Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Cytomegalovirus (CMV) Tests Market - By Sample Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Sample Type, 2023 & 2032 (%)
    • 7.1.2. Urine
    • 7.1.3. Blood

8. Cytomegalovirus (CMV) Tests Market - By Drug Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Drug Type, 2023 & 2032 (%)
    • 8.1.2. Valganciclovir
    • 8.1.3. Ganciclovir
    • 8.1.4. Cidofovir
    • 8.1.5. Foscarnet
    • 8.1.6. Others

9. Cytomegalovirus (CMV) Tests Market - By Test Type

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Test Type, 2023 & 2032 (%)
    • 9.1.2. Enzyme immunoassay/enzyme-linked immunosorbent assay (EIA/ELISA) tests
    • 9.1.3. Nucleic acid amplification tests (NAATs)
    • 9.1.4. Other CMV tests

10. Cytomegalovirus (CMV) Tests Market - By End User

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By End User, 2023 & 2032 (%)
    • 10.1.2. Hospitals
    • 10.1.3. Diagnostic Centres
    • 10.1.4. Clinics
    • 10.1.5. Others

11. Cytomegalovirus (CMV) Tests Market - By Application

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 11.1.2. Retinitis
    • 11.1.3. Pneumonia
    • 11.1.4. Gastrointestinal ulcers
    • 11.1.5. Encephalitis
    • 11.1.6. Stem cell transplantation
    • 11.1.7. Organ transplantation
    • 11.1.8. Others (Mouth Ulcers, Pharyngitis, etc.)

12. Cytomegalovirus (CMV) Tests Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Cytomegalovirus (CMV) Tests Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Cytomegalovirus (CMV) Tests Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Sample Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Drug Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Test Type, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Cytomegalovirus (CMV) Tests Industry

  • 13.1. Competitive Dashboard
  • 13.2. Company Profiles
    • 13.2.1. Pfizer Inc.
    • 13.2.2. GlaxoSmithKline plc
    • 13.2.3. Novartis AG
    • 13.2.4. Mylan N.V.
    • 13.2.5. Teva Pharmaceutical Industries Ltd.
    • 13.2.6. Sanofi
    • 13.2.7. F. Hoffmann-La Roche Ltd.
    • 13.2.8. Zydus Cadila
    • 13.2.9. Lupin
    • 13.2.10. Cipla Inc.
    • 13.2.11. Aurobindo Pharma
    • 13.2.12. Glenmark Pharmaceuticals Limited
    • 13.2.13. Endo International plc
    • 13.2.14. AstraZeneca
    • 13.2.15. Johnson & Johnson Private Limited
    • 13.2.16. Bio-Rad Laboratories, Inc.
    • 13.2.17. BD
    • 13.2.18. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us